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The purpose of this article is to provide
the medical practitioner with an under-
standing of lipids, lipoproteins and their
metabolism and disorders. Such an
understanding would enhance the assimi-
lation of the sections on clinical assess-
ment and treatment of dyslipopro-
teinaemia.
Lipids may be defined as organic chemi-
cals that are insoluble in water. In the
biological context lipids are either car-
boxylic acids (fatty acids) or sterols, and
their derivatives. Lipids are less dense
than water and will float spontaneously or
under centrifugal force. Cholesterol  is
the principal sterol in the animal kingdom
and promotes the impenetrability of the
phospholipid bilayer that constitutes the
cell membrane. Additionally cholesterol is
found in lipoproteins and in bile and is
used to synthesise hormones and bile
acids. Cholesterol is stored and transport-
ed in an esterified form with fatty acids.
Salts of fatty acids  are detergents that
would disrupt associations of lipids such
as membranes. For this reason their con-
centration in the body is low and they are
carried on albumin or other proteins for
protection. Fatty acids are the building
blocks of phospholipids (glycerol with 2
fatty acids, a phosphate and a polar group
such as choline, ethanolamine or serine)
and triglyceride (glycerol with 3 fatty
acids) as well as more complex lipids.
Fatty acids serve as energy substrates that
are transported and stored as triglyc-
erides.They also have a structural role in
cell membranes, as well as recently recog-
nised roles in targeting proteins to cell
membranes.
Cells utilise fatty acids for energy through
β-oxidation, as structural components in
phospholipids and for energy storage as
triglycerides. The fatty acids can be taken
up from the environment directly or by
taking up more complex lipids and digest-
ing them in the lysosomes. The growth of
cells demands cholesterol for membrane
formation.This demand is met by de novo
synthesis of cholesterol (in which
HMGCoA reductase is the rate-limiting
enzyme), expression of  low-density
lipoprotein (LDL) receptors to take up
circulating lipoprotein as a ready source of
cholesterol and hydrolysis of cholesterol
ester, the storage form of cholesterol.
Cells that have high demands for choles-
terol utilise the same mechanisms for cho-
lesterol balance when they are mature:
hepatocytes, adrenocytes and enterocytes.
Mature cells that do not have a demand
for cholesterol may accumulate this sterol
even if the de novo synthesis is down-regu-
lated along with receptor expression. In
this setting, recently discovered adenosine
cassette-binding proteins are utilised to
promote cholesterol efflux, as well as
organelles called caveolae.
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An understanding of lipid metabolism and its dis -
orders is increasingly necessary to the GP in this
era of sedentary lifestyles and over-indulgence.
Lipids may be defined as
organic chemicals that
are insoluble in water.
In the  biological con -
text lipids are either car -
boxylic acids (fatty
acids) or sterols, and
their derivatives.
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LIPOPROTEINS
Lipids need to be transported and
targeted for specific sites and pur-
poses in the body. Although they
have different functions, the lipids
will associate with one another
owing to their insolubility in an
aqueous environment.These asso-
ciations also involve special pro-
teins, called apolipoproteins or
apoproteins. The whole particle,
comprising  lipid and protein, is
called a lipoprotein.The structure
of a lipoprotein typically involves
the assembly of the more polar
lipids, phospholipid, free choles-
terol and protein on the exterior of
a sphere where they can interface
with the aqueous environment, and
neutral lipids such as cholesterol
ester and triglyceride, in the cen-
tre.
The properties of lipoproteins are
described in Table I. It can be
seen that triglyceride is the major
component of the larger lipopro-
teins which are also the least dense
as a result of the low specific gravi-
ty of lipids. The large diameters of
chylomicrons (CM) and very low-
density lipoprotein (VLDL) result
in the scattering of light and hence
turbidity of plasma.The choles-
terol-rich  particles contain  more
protein, increasing the density to
LDL which also contain
apolipoprotein B (apoB) as it is the
final product of VLDL metabolism
(Fig. 1), and high-density lipopro-
teins (HDL) in which the most
prominent apoprotein is apoAi.
Except for apoB, all other apopro-
teins can exchange between
lipoproteins. Apoproteins serve as a
nidus for phospholipids to initiate
the formation of lipoproteins, as
ligands for receptors and modula-
tors of enzyme activities. The
conformation permits apoB to be a
ligand for the LDL receptor only
on LDL, while apoE is a ligand for
this receptor and other LDL recep-
tor-like proteins irrespective of the
lipoprotein on which it resides.
ApoAi, apoAii and apoAiv are
involved in the development of
HDL. ApoCii activates and apoCiii
inhibits lipoprotein lipase (LPL).
Apo(a) is a protein that is linked to
apoB on an LDL-like particle. It
resembles haemostatic proteins and
may have an antifibrinolytic and
wound-repair function.
The assembly of chylomicrons and
VLDL is by a specialised mecha-
nism in enterocytes and hepato-
cytes. A large protein, apoB, serves
as the template for assembly of
triglyceride: in the hepatocyte the
whole gene (B100) is employed
while in the enterocyte the mRNA
of this gene is edited to code for
apoB48.The intracellular neutral
lipid is added to the apoB by
microsomal triacylglycerol transfer
protein (MTP).
In the circulation, lipoproteins
undergo continuous modification.
On the vascular endothelium of
muscle and adipose tissue, held in
place by proteoglycans, is LPL
which, in the presence of apoCii,
will hydrolyse triglycerides. At the
liver, hepatic lipase has a similar
action but acts also on smaller
lipoproteins that contain triglyc-
eride. Lecithin:cholesterol acyl
transferase (LCAT) acts mainly on
HDL to convert free cholesterol to
cholesterol ester which, upon mov-
ing into the core of HDL as a neu-
tral lipid, will create a space for
more cholesterol in the phosholipid
shell of the particle. Cholesterol
ester transfer protein (CETP)
exchanges neutral lipid between
lipoproteins, but owing to the rapid
catabolism and removal of triglyc-
eride-rich lipoproteins, there is a
nett transfer of cholesterol from
HDL and of triglyceride to HDL.
In hypertriglyceridaemia, the
enrichment of LDL and HDL with
triglyceride makes them suscepti-
ble to a reduction in size by  hepat-
ic lipase. Paraxonase is an enzyme
present on HDL and is involved in
the metabolism of oxidatively mod-
ified fatty acids. Several other pro-
teins that are associated with




A convenient division of  lipopro-
tein metabolism identifies 5 path-
ways: (1) an exogenous lipid path-
Density Size Protein Triglyceride Cholesterol
Lp (g/ml) (nm) (% mass) (% mass) (% mass) Apoproteins
CM <0.95 75  - 1200 1 - 2 85 - 90 5 - 8 B48, A, C, E
VLDL 0.95 -1.006 30 - 80 6 - 12 55 - 65 15 - 20 B100, A, C, E
IDL 1.006 -1.019 25 -35 10 - 20 15 - 30 20 - 30 B100, C, E LDL
1.020 - 1.063 18 - 25 20 - 25 8 - 12 42 - 48 B100
Lp(a) 1.055 - 1.095 27 - 32 25  - 35 3 - 12 35 - 45 B100, (a) 
HDL2 1.063 - 1.112 9 - 12 35 - 45 6 - 10 22 - 28 A, C, E
HDL3 1.112 -1.210 3 - 5 50 - 60 3 - 5 15 - 18 Ai, Aii
CM = chylomicrons; VLDL = very low-density lipoprotein; IDL = intermediate density lipoprotein consisting mainly of remnants of VLDL; LDL = low-density lipoprotein; Lp(a)
= lipoprotein ‘little a’; H DL = high-density lipoprotein.
Table I. Properties of lipoproteins
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way for dietary lipids, (2) an
endogenous triglyceride pathway
which also has a component that
yields (3) LDL as a source of cho-
lesterol, (4) reverse cholesterol
transport and (5) lipoprotein (a).
A sixth consideration may be the
complex in plasma of albumin and
free fatty acids. The latter two
pathways are not considered in
detail in this review.
The exogenous pathway distributes
dietary cholesterol and fatty acids.
Dietary lipids comprise mainly
triglyceride and cholesterol but
some phospholipid and cholesterol
ester will also be present, as well as
the plant sterols (phytosterols
include sitosterol, campesterol and
others) that are not assimilated.
The pancreatic enzymes digest
these dietary lipids to fatty acids
and cholesterol before the entero-
cyte re-assembles triglyceride and
phospholipid to package into the
CM along with the absorbed cho-
lesterol from dietary and biliary
origin.The CM pass through the
thoracic duct to the systemic circu-
lation where most of their apopro-
teins are obtained through redistri-
bution from HDL.The apoCii
thus obtained will activate the LPL
on the endothelium of muscle and
adipose tissue, as well as in breast
tissue under appropriate hormonal
stimulation.The fatty acids
released by lipolysis serve the fol-
lowing purposes: energy sub-
strate, energy stores and the
preparation of milk. In the process
during which the core of the CM is
reduced in size, the redundant
phospholipid on the surface buds
off with apoAi to form HDL and
‘CM-remnants’ form.The apoE on
these remnants acts as the ligand
for the LDL receptor and the LDL
receptor-related protein so that the
remaining triglyceride and the
dietary cholesterol may be
returned to the liver.The digestion
and absorption and packaging of
dietary lipid delays the appearance
of CM in the circulation but a rise
in triglyceride concentration and a
slight turbidity of plasma can be
expected 3 hours after a fatty meal.
A 10 - 12-hour fast should allow
for complete disposal of CM from
the circulation.
The endogenous triglyceride path-
way could be viewed as parallel to
the exogenous pathway for triglyc-
eride distribution between meals.
The VLDL triglyceride also under-
goes lipolysis by activated LPL and
produces HDL and remnants.The
bulk of the VLDL remnants is
cleared by virtue of apoE, but a
small proportion forms LDL.This
pathway sustains the fasting
triglyceride concentration.
During the transformation of
VLDL remnants to LDL, a process
thought to be dependent in part on
hepatic lipase, all apoproteins other
than apoB are lost and apoB
assumes the correct conformation
to bind the LDL receptor (also
called the B,E receptor).This
lipoprotein provides the bulk of the
total cholesterol in the plasma of
humans and acts as the source of
cholesterol for cells which require
this substance.
The process that can remove cho-
lesterol from somatic cells and
return it to the hepatocyte to satis-
fy its needs for cholesterol (choles-
terol and bile acid synthesis for
bile), is called reverse cholesterol
transport. Cells which have low
demands for cholesterol may still
accumulate it in excess from
(down-regulated) de novo synthesis
and nonspecific uptake from the
exterior. The cell responds to
apoAi on HDL by transporting
cholesterol to the surface with an
adenosine binding cassette trans-
porter protein, ABCA1.
Phospholipid and cholesterol trans-
fer to apoAi to form the nascent
lipoprotein that commences the
HDL pathway. At this point LCAT
will further develop HDL by form-
ing cholesterol ester with a fatty
acid from phospholipid, resulting
in a transfer to the core.
Cholesterol ester in turn, will be
exchanged by CETP into the
triglyceride-rich lipoproteins which
are destined to return to the liver.
The cholesterol ester may also be
delivered in HDL through scav-
enger receptor B1 on the liver.
In the normal subject who has fast-
ed, the liver sustains a triglyceride
concentration of 1.5 mmol/l  that
is for a large part supported by the
influx of fatty acids from adipose
tissue. Consider the course of
Fig. 1. Lipoprotein metabolism in plasma. The lipoproteins are not drawn to
scale. 
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events after consuming 200 g of
chocolate that represents 80 g of
triglyceride (or 100 mmol). The
CM will enter the plasma from
about half an hour after the meal.
The concentration rises to a peak
after about 3 hours when it
becomes turbid, and finally all
dietary triglyceride will leave the
circulation by catabolism and
clearance. If no triglyceride is
cleared, the 100 mmol of triglyc-
eride would change the plasma
concentration by 33 mmol/l.
Plasma of a normal fasting subject
eating a low-cholesterol diet will
have an LDLC concentration of
about 3 mmol/l. When the diet is
enriched with cholesterol, the cho-
lesterol meal of 2 egg yolks
(approximately 1.2 mmol) will not
be detectable even at the peak con-
centration of CM but the delivery
of cholesterol to the liver will load
the hepatocyte with cholesterol and
will down-regulate the LDL recep-
tors, leading to the establishment
of a new, higher, steady-state con-
centration of LDL — on average,
by about 1.5 mmol/l higher. The
plasma HDLC is about 1.2 mmol/l
and that in VLDL is about 
0.8 mmol/l.The sum of these fig-




containing lipoproteins and HDL
hypocholesterolaemia are the result
of an interplay of environmental
and genetic factors and are corre-
lated with atherosclerosis.
Atherosclerosis is a complex
process in arteries, involving
inflammation and lipid accumula-
tion and has the potential of
becoming complicated by clinically
manifest vascular disease. In severe
derangements of lipoprotein
metabolism, generally charac-
terised as autosomal dominant or
recessive illnesses, the physical
signs and the high risk of compli-
cation make for easy clinical and
biochemical recognition.
Pancreatitis is the consequence of
hypertriglyceridaemia which may
also be a clinically recognisable
phenotype.
A convenient classification of dys-
lipidaemia, as described in Table II,
is based on the commonly mea-
sured total cholesterol and triglyc-
erides and concerns hyperlipi-
daemias of apoB-containing
lipoproteins. It is important to con-
sider the contributions of HDL
and LDL separately to better
understand the risk of atheroscle-
rosis. Mixed dyslipidaemia and
hypertriglyceridaemia may be due
to accumulation of single lipopro-
tein species or combinations of
lipoproteins. LDL that has modu-
lated to a small size by triglyceride
enrichment is pro-atherogenic.
A lipoprotein species changes its
concentration as a result of a dif-
ferent production and/or clearance
rate — these may be primary or
secondary. The primary causes for
dyslipoproteinaemia are indicated
in Table III.The classification given
here describes the range of disor-
ders that can be determined by
performing cholesterol and triglyc-
eride concentrations.The complete
lipid profile is best assessed after
full lifestyle modification.The fast-
ing profile is important for provid-
ing the triglyceride concentration
Pancreatitis is the
consequence of
h y p e r t r i g l y c e r i -
daemia which may
also be a clinically
recognisable pheno -
t y p e .
Hypercholesterolaemia Mixed Hyperglyceridaemia
Severe Moderate Mild hyperlipidaemia Moderate Severe
TG < 1.5 1.5 - 5 5 - 15 > 15
TC > 7.5 > 5.0 > 5.0 Variable Variable
LDLC > 5.0 > 4.0 > 3.0 Variable Variable Little to none
Small dense LDL in all hypertriglyceridaemias
IDLC Negligible contribution Dysbetalipoproteinaemia
Lp(a) Negligible contribution
HDLC >1.6 Low HDLC with 
hypertriglyceridaemia
LpX Cholestasis
TG = triglyceride; TC = total cholesterol; IDLC = intermediate-density lipoprotein cholesterol; LD LC  = low-density lipoprotein cholesterol; H DLC = high-density lipoprotein
cholesterol; LpX = lipoprotein X. 
It is important to consider HDL as a significant contributor to moderate and severe hypercholesterolaemia as it is usually a negative risk factor. IDLC usually contributes
negligibly to pure hypercholesterolaemia while I DLC increases in dysbetalipoproteinaemia which can also cause severe hyperglyceridaemia.   Lipoprotein X occurs with
high concentrations of bile acids. 
Table II. Clinical classification  of primary causes of dyslipoproteinaemia
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from which LDL cholesterol is cal-
culated but LDL cholesterol can
also be measured by direct means.
High LDL concentration as a
result of decreased clearance may
be due to mutations in the LDLR
gene (familial hypercholestero-
laemia (FH) or apoB (familial
binding defective B100, (FBD)).
This pattern is called type II
hyperlipidaemia in the Fredrickson
classification. Overproduction of
VLDL is thought to be the cause
of familial combined hyperlipi-
daemia (FCH) and the lipoprotein
phenotype within the family varies
considerably according to the pres-
ence of relatively minor additional
genes: increases of LDL, and/or
VLDL (type IIb or when VLDL is
predominant, type IV).These dis-
orders are dominantly inherited.
Dysfunctional apoE delays the
clearance of remnant lipoproteins
Pattern Primary cause(s) Clinical manifestations
CM LPL deficiency Recessive; childhood to young adulthood; severe
ApoCii deficiency hypertriglyceridaemia, pancreatitis; rare but present in 
South Africa
CM, VLDL FHTG Dominant; poorly understood
FCH Dominant; overproduction of VLDL but dietary fat or genes in 
lipolytic cascade may increase CM; sometimes eruptive 
xanthomata
VLDL FHTG, FCH No physical signs
IDL ApoE mutations Dyslipidaemia only in adult; some have cutaneous, palmar & 
tendinous xanthomata; mostly apoE2/2 that requires 
additional trigger but also dominant forms; uncommon
LDL LDL receptor (FH) Dominantly inherited; adults commonly display tendon 
xanthomata, corneal arcus, premature ischaemic heart
disease; LDL clearance limited; world-wide prevalence about 
0.2% but founder effects in South Africa: 1% Afrikaners;
homozygous FH displays cutaneous & tendinous xanthomata 
with highly premature ischaemic heart disease; very rarely a 
recessive phenocopy is due to deficiency of adaptor 
protein for LDLR
ApoB (FDB) Phenocopy of FH but rare in South Africa
FCH Dominant, variable pattern in family; no physical signs, about 
2% of population
Small dense LDL Poorly understood causes, about 20% adults, typical of insulin 
resistance
Phytosterolaemia Very rare, recessive; phenocopy of hoFH with moderate 
hypercholesterolaemia only
Absent apoB Hypobetalipoproteinaemia Dominant, uncommon; low cholesterol and
triglyceride in heterozygote; homozygous state has extremely
low cholesterol, stunted development, retinitis pigmentosa 
and neuromuscular degeneration
Abetalipoproteinaemia Recessive, rare; defect of MTP required to assemble 
lipoproteins; phenocopy of homozygous 
hypobetalipoproteinaemia
Low HDL ApoAi defects Rare; some confer low HDL and heart disease
LCAT deficiency Rare, dominant; renal disease or clouded cornea (fish eye 
disease)
Tangier disease Rare, dominant; adenosine binding cassette transporter 
defect disrupts reverse cholesterol transport; homozygote 
may display hepatosplenomegaly and tonsillar enlargement
High HDL CETP deficiency Rare, dominant; atherogenic as reverse cholesterol
transport may be disrupted; mainly reported from the Orient
CM = chylomicrons; VLDL = very low-density lipoproteins; IDL = intermediate-density lipoproteins (remnants); HDL = high-density
lipoproteins; LPL = lipoprotein lipase; FHTG = familial hypertriglyceridaemia; FCH = familial combined hyperlipidaemia.  
Table III. Mechanisms and manifestations of primary dyslipoproteinaemia 
phenotypes
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which accumulate as dysbeta-
lipoproteinaemia (type III hyperlip-
idaemia).There are recessive and
dominant forms of dysbetalipopro-
teinaemia.The commonest setting
for dysbetalipoproteinaemia is the
homozygous state of apoE2, which
delays remnant clearance, together
with some other genetic or envi-
ronmental factor that stresses pro-
duction of VLDL or clearance by
LDLR. The accumulation of CM
alone, as a result of deficiency of
LPL or its activator apoCii, is type
I hyperlipidaemia and is recessively
inherited.The accumulation of
VLDL and CM, known as type V
hyperlipidaemia, is usually the
result of overproduction and
underclearance of lipoproteins. It
represents an interplay of dietar y
fat, lipase activity and other
apoprotein variations.
Severe hypocholesterolaemia 
(< 2.5 mmol/l) is the result of an
inability to produce apoB-contain-
ing lipoproteins. In hypobeta-
lipoproteinaemia, the heterozygotes
have very low LDL concentrations
and may have offspring who have
no detectable LDL,VLDL and
CM.This causes malabsorption
and oxidation of lipids in the eye
and neuromuscular dysfunction.
Vitamin E can only be assimilated
through CM.The same phenotype,
abetalipo p r o t e i n a e m i a , m ay be the
result of the recessively inheri t e d
defects in MTP. H y p o c h o l e s t e r o -
laemia due to an inability to syn-
thesise cholesterol is associat e d
with severe phenotypic sequelae.
Very low HDL cholesterol concen-
trations may be seen as a recessive
trait with defects in the adenosine
binding cassette transporters that
enable cholesterol to efflux into
HDL, while there are also domi-
nantly inherited diseases as a result
of mutations of apoAi and LCAT.
High HDL concentrations may be
seen in CETP deficiency, a condi-
tion that may be  atherogenic as a
result of impaired reverse trans-
port.
Rare, recessively inherited meta-
bolic errors of sterol metabolism
include phytosterolaemia (overab-
sorption of plant sterols resulting
in xanthomata and atherosclerosis)
and cerebrotendinous xanthomato-
sis (impaired cholesterol oxidation
resulting in accumulation of
cholestanol resulting in xanthoma-
ta, cataracts and leucodystrophy).
These disorders are associated with
normal plasma cholesterol concen-
trations.
IN A NUTSHELL
Fatty acids are important sources of
energy and are esterified onto glyc-
erol to form triglycerides and phos-
pholipids. The former serve as a trans-
port and storage mechanism for ener-
gy in the body while the latter are
structurally crucial for cell mem-
branes.  Fatty acids also form esters
with cholesterol which can be stored
in cells or be transported in lipopro-
teins.  
Dietary fat is digested to the compo-
nent fatty acids and cholesterol before
assimilation by the enterocyte which
metabolises them to triglyceride and
cholesterol ester before incorporating
these into CM. MTP assembles the
lipids on apoB48. LPL and Cii are cru-
cial for processing CM and apoE is
necessary to clear CM remnants.
Postprandially, triglycerides in CM are
processed rapidly and efficiently. The
contribution from dietary cholesterol
to the total plasma cholesterol is small
immediately after the meal but regula-
tion of the LDLR results in significant
changes over weeks. 
The liver sustains plasma triglycerides
by the production of VLDL, using
apoB100 and MTP for assembly.
VLDL is metabolised in a similar man-
ner to CM; the VLDL remnants clear-
ing by virtue of apoE. In contrast to
CM, a proportion of the VLDL rem-
nants is metabolised to LDL. LDL car-
ries most of the plasma cholesterol in
humans and is cleared by the binding
of apoB to the LDLR.  It is athero-
genic, especially when smaller and
denser, a modulation that can happen
with mild hypertriglyceridaemia.
Reverse cholesterol transport begins
intracellularly with ABC A1 which per-
mits the export onto  apoAi and phos-
pholipid complexes. LCAT allows
more cholesterol assimilation onto
HDL.  CETP transfers cholesterol ester
to other lipoproteins for delivery to
the liver but cholesterol ester can a l s o
be transferred to the liver dire c t l y. 
Familial hypercholesterolaemia (FH) is
a common metabolic error world-wide
and is even more common in several
South African communities. It is due
to mutations in the LDLR.
Heterozygous FH is characterised by
an increase in LDLC (>5 mmol/l),  ten-
don xanthomata and premature hear t
disease. Familial binding defective
apoB is phenotypically similar. Familial
combined hyperlipidaemia (FCH) is
also characterised by dominant inheri -
tance but there may be  family mem-
bers with different hyperlipidaemia
patterns and tendon xanthomata are
absent.  
Dysbetalipoproteinaemia is a mixed
hyperlipidaemia due to dysfunction of
apoE.  Severe hypertriglyceridaemia
due to CM accumulation is seen with
homozygous LPL or homozygous
apoCii deficiency. When apoB is trun-
cated to the extent that it cannot
assimilate lipid, or when MTP is
absent, the failure of CM production
causes malabsorption and low post-
prandial triglycerides and the failure of
VLDL production results in very low
cholesterol concentrations. 
